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Abstract
5-fluorouracil (5FU), a widely used chemotherapeutic drug, inhibits the DNA replicative enzyme, thymidylate synthase
(Tyms). Prior studies implicated a VNTR (variable numbers of tandem repeats) polymorphism in the 59-untranslated region
(59-UTR) of the TYMS gene as a determinant of Tyms expression in tumors and normal tissues and proposed that these VNTR
genotypes could help decide fluoropyrimidine dosing. Clinical associations between 5FU-related toxicity and the TYMS
VNTR were reported, however, results were inconsistent, suggesting that additional genetic variation in the TYMS gene
might influence Tyms expression. We thus conducted a detailed genetic analysis of this region, defining new
polymorphisms in this gene including mononucleotide (poly A:T) repeats and novel single nucleotide polymorphisms
(SNPs) flanking the VNTR in the TYMS genetic region. Our haplotype analysis of this region used data from both established
and novel genetic variants and found nine SNP haplotypes accounting for more than 90% of the studied population. We
observed non-exclusive relationships between the VNTR and adjacent SNP haplotypes, such that each type of VNTR
commonly occurred on several haplotype backgrounds. Our results confirmed the expectation that the VNTR alleles exhibit
homoplasy and lack the common ancestry required for a reliable marker of a linked adjacent locus that might govern
toxicity. We propose that it may be necessary in a clinical trial to assay multiple types of genetic polymorphisms in the TYMS
region to meaningfully model linkage of genetic markers to 5FU-related toxicity. The presence of multiple long (up to
26 nt), polymorphic monothymidine repeats in the promoter region of the sole human thymidylate synthetic enzyme is
intriguing.
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Introduction
5-Fluorouracil (5FU) was developed by Heidelberger and
colleagues [1] as the first generation of chemotherapeutic agent
active for gastric cancer. Over time, this drug had been widely
used to treat malignancies of the breast, head and neck, and other
solid tumors in cancer patients. 5FU causes cell death by
incorporating fluorinated nucleotides into DNA and RNA, by
covalent binding of its metabolites with Tyms protein, and by
inhibiting cell growth through disruption of rRNA processing by
the exosome complex [2,3,4,5,6]. An orally administered analog,
capecitabine, is converted metabolically to 5FU.
5FU dosing is typically based on the body surface area of the
patient; however, it has not been well standardized Yet, this
practice is associated with high amount of variability in plasma
5FU levels, up to 100-fold [7], leading to undesired side-effects.
This interpatient and intrapatient variability may be a major
contributor to toxicity and subsequent treatment failure [8,9].
Dose management of 5FU could therefore prove essential to
reducing 5FU toxicity in patients.
Multiple variables might affect 5FU therapy. TYMS genetic
polymorphisms in the 59- and 39-UTR have been studied for
decades and proposed to influence Tyms protein levels. The 28 bp
variable number of tandem repeats (VNTR) in the TYMS 59UTR
has been studied extensively. Although up to nine repeats have
been observed, the double repeat (2R) and the triple repeat (3R)
are far more prevalent [10,11]. A single G/C nucleotide
polymorphism in the 3R sequence gives rise to a 3Rc or a 3Rg
triple repeat structure [11]. A 6-bp insertion/deletion polymor-
phism in the 39-UTR of the gene is also described [12]. Prior
studies supported these 59UTR repeats as important determinants
of Tyms expression in tumors and normal tissues and proposed
that the TYMS VNTR genotypes could be used to help decide
fluoropyrimidine dosage in patients [13,14,15]. This proposal
however lacked a strong ‘in-vitro’ experimental basis (see refutation
in [16]).
Several clinical trials were conducted in the light of the above
proposal using germline genotype data, which can differ
significantly from the aneuploid tumor’s genotype. These studies
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gene predicted 5FU-related toxicity [17,18,19,20] while another
study concluded that none of the TYMS UTR polymorphisms
could explain 5FU-related toxicity or clinical outcome [21]. Some
studies suggested that patients with the 2R/2R genotype had a
higher likelihood of suffering from grade 3–4 toxicity in response
to 5FU-based therapy as compared to patients with 3R/3R
genotype [19]; the results of these studies were largely inconsistent
and presented a broad range of odds ratios. A recent Blue Cross
Blue Shield (BCBS) opinion (BCBS report, Volume 24, No. 13,
August, 2010) refuted these toxicity studies and concluded that the
determination of the VNTR alone could not reliably predict
toxicity from 5FU.
We therefore wanted to reexamine this subject. We suspected
that the literature could be reconciled were there an extended
genetic haplotype in the TYMS 59UTR, perhaps predictive of 5FU
toxicity. The mononucleotide repeats and SNPs in this region have
received little published attention. It would be important to
characterize these additional polymorphisms in order to define a
‘complete’ genotype of an individual. To better understand these
findings we first conducted a detailed genetic analysis of the TYMS
locus. Through detailed sequence analysis, we report three types of
polymorphisms in this region: the known VNTRs, mononucleo-
tide repeats of the promoter region, and the SNPs of the wider
genomic context. These polymorphisms when taken together, but
not in isolation, define the genotype of an individual, and
knowledge of linkage disequilibrium among them might provide
clues to understand variation in 5FU-related toxicity in patients.
Results
Characterizing three polymorphic forms in the TYMS
59UTR by sequencing
The VNTR types, namely 2R, 3Rc, and 3Rg, were ascertained
for both alleles from constitutional DNA in 40 pancreatic cancer
patients (Table 1). Of these 40 patients, 31 were Caucasian and
their VNTR types were included in our haplotype analysis (details
below); linkage disequilibrium structure varies between different
populations, and haplotype analysis is known to be population-
specific. The twelfth nucleotide in each 28-bp VNTR is a G or a C
such that the wild-type sequence is 2RGC (2R, in this study) for
the two-repeat VNTR, and 3RGGC (3Rg, in this study), for the
three-repeat VNTR. We observed the 3RGCC polymorphism in
several individuals (3Rc, in this study) and include this polymor-
phism in our analysis. We, however, failed to identify 2RCC,
2RGG, and 3RCCC polymorphisms (rare polymorphisms report-
ed [22,23]) in the 80 chromosomes genotyped in this study and in
another 100 chromosome genotyped earlier (data not shown) and
therefore do not include these rare polymorphisms in our
haplotype analysis.
We identified some SNPs, not reported hitherto in the public
databases, by sequencing 15 kb upstream of the TYMS ATG
(Figure 1A), using primer pairs spanning 400–500 bp each. We
noted 25 SNPs in this 15 kb region, of which 22 are currently in
public databases. The remaining three novel SNPs (included in
Table S1) were infrequent and were not contributory to our
analysis.
Several arrays of mononucleotide repeats in the TYMS
promoter region were encountered. Three stretches of A’s (or
T’s) were located about 750 bp upstream of the ATG and an
additional three stretches were located another 1.5 kb upstream
(Figure S1). The existence of the mononucleotide repeats made
these regions extremely difficult to sequence due to polymerase
stutter. In order to resolve the lengths, we attached a 59FAM (5-
carboxyfluorescein) molecule to the forward primers and used
capillary electrophoresis [(CE), ABI 3130] assay to estimate the
number of bases. We analyzed these repeat stretches in 32
individuals and found polymorphism in some repeats, discussed in
detail below. Repeat polymorphism was confirmed by mixing
templates of individuals exhibiting differing repeat lengths,
followed by the CE assay (Tables 2, 3).
Length analysis of mononucleotide repeats
Mononucleotide repeats could be useful as markers for genetic
mapping. In addition to being abundant, they have considerable
length variability or polymorphism. The presence of six stretches
of mononucleotide repeats (MR) (Figure S1; Table 2), particularly
poly (A) and poly (T), within 2 kb upstream of the TYMS promoter
region (Figure S1), was unusual. Among the 32 individuals studied
for repeat lengths, repeats MR2, MR3, and MR6 had length
polymorphism (Table 2), ranging between 1- to 5-bp variation.
Additional variation could have evaded our study, due to
polymerase stutter and due to difficulty in resolving the closely
located MR5 and MR6 repeats (Figure S1). A 1-bp difference was
considered as within the variation of the instrument [standard
deviation of 0.04 to 0.24 nucleotides, [24]] but greater differences
were considered a polymorphism of repeat lengths. As shown in
Table 3, MR2 locus had the most variation (2–5 bp) from among
the six repeats analyzed. Using ‘‘peak width’’ measured at the half-
maximal points of a peak in each sample, we created mixtures of
samples having variation in DNA lengths; in this manner, we
further confirmed that the repeat was indeed polymorphic.
Specifically, samples PN9 and PN104 (having a 3-bp difference)
were mixed in different ratios. The results revealed a broader peak
in the mixed samples as compared with the individual samples
(depicted in Table 3). The graphs of the primary data produced by
the mixed samples had a skewed appearance, as expected,
representing the predominant sample in the mixture (data not
shown) when the degree of mixture was modified (Table 3).
SNP genotyping and haplotype structure of TYMS
genetic region
We examined an 80 kb stretch from the TYMS genetic region
(Figure 1A) to infer the haplotype structure from the SNPs in the
region and to determine whether the SNPs were in linkage
disequilibrium (D9, a numerical representation of correlation with
other forms of polymorphism [25]). We chose 133 SNPs (Table
S2) from HapMap and our sequencing data (Table S1), and we
studied their distribution in our 351 individuals. Several haplotype
blocks numbered 1 to 9 (Figure 1B) were found in this region. The
boxes in red or pink (Figure 1B) depict D9 to have very good
dependency, or correlation, between SNPs, as shown in the color
legend in Figure 1. The boxes in blue or white indicate D9 to have
poor dependency, or correlation, between SNPs. D9 is indicated in
Table 1. VNTR genotypes among 40 genomes.
Genotype Count
2R/2R 10
2R/3Rc 10
2R/3Rg 7
3Rc/3Rg 6
3Rg/3Rg 4
3Rc/3Rg 3
doi:10.1371/journal.pone.0034426.t001
TYMS Polymorphisms
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34426Figure 1. Haplotype structure of the TYMS genetic region. A. Linear map of the 80 kb TYMS genetic region covering the TYMS gene
(coordinates 657,604–673,499), upstream region (600,000–657,603) and downstream region (673,500–680,000). All coordinate positions are according
to UCSC genomic build GRCh37/hg19. SNPs along this region were selected from the HapMap database (see Materials and Methods) and from our
sequence analysis. B. Nine haplotype blocks (in triangular shape), numbered 1 to 9, were obtained by haplotype analysis using Haploview (see
Materials and Methods). The reference SNP numbers (rs) are indicated on top. The linkage disequilibrium (D9) is indicated in the small boxes colored
red or blue (a color legend is provided). Some newly discovered SNPs that were not in the public database at the time of analysis were named as
TYMS_SG 1, 2, 3, 16,19, 22, and 24. At the time of submission of the new SNPs, we noticed they were deposited by others and had assigned SNP
numbers of rs12964837, rs11872762, rs11877806, rs36124867, rs75363899, rs2853533, and rs72634355 respectively. C. The largest haplotype block
spanning the TYMS gene and some parts in the 59 UTR, including the VNTR and the mononucleotide repeats, and the 39UTR, is expanded. Blocks 1
and 2 in this figure corresponds to blocks 8 and 9 respectively, of Figure 1B. The unmatched marker 87 corresponding to SNP number rs3826626 (in
panel B) was removed in this figure. The locations of the VNTR, MR (mononucleotide repeats), and the 6-bp deletion/insertion polymorphism are
shown. The TYMS translational start codon is 13 bp downstream of the VNTR. Enlarged versions of figures B and C are provided in supporting
information as figure S2 and figure S3, respectively.
doi:10.1371/journal.pone.0034426.g001
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largest haplotype block spanned the TYMS gene and some parts
upstream, including the VNTR and the mononucleotide repeats
(Figure 1C; enlarged version in Figure S3), indicating that the
SNPs in the region were very strongly associated with each other.
The nine common SNP haplotypes identified in this block
(Figure 2) accounted for nearly 92% of the variation among the
tested population. The most common haplotype was found on
42% of chromosomes.
Relationship between SNP haplotypes and VNTR
The correlation between these haplotypes and the VNTR was
weak (depicted in Figure 3). While the frequency of the VNTR
alleles varied by haplotype, the same VNTR allele occurred on
different haplotype backgrounds at varying frequencies (Figure 3).
The VNTR type ‘2R’ was present in the most-common haplotype
(36% of alleles); the VNTR type ‘3Rg’ was present in the second-
most-common haplotype (10% of alleles), and so on. Our analysis
indicated that the 59UTR VNTR appears to exhibit homoplasy
(mechanism of inheritance by convergence, parallelism or reversals
and not by common ancestry) [26,27,28] and is more rapidly
evolving than the SNP haplotypes, as discussed below. Due to the
homoplasious nature of the TYMS VNTR, we limited the TYMS
59UTR genotyping to 40 individuals. Determination of the VNTR
type in additional individuals would not have altered our
conclusion about the weak association of the VNTR and SNP
haplotypes.
Relationship between SNP haplotypes and 6-bp 39UTR
insertion/deletion polymorphism
A 6-bp insertion/deletion polymorphism (TTAAAG) in the 39-
UTR of the thymidylate synthase gene was proposed to influence
Tyms expression [29,30] and 5FU-related toxicity in patients [31]
in several studies. This polymorphism occurred in less than 20% of
the chromosomes analyzed and was observed on multiple
haplotype backgrounds (results not shown).
Discussion
We define a detailed genetic map of the TYMS 59-genetic region
comprising three types of polymorphisms and propose that
knowledge of this variation and of the linkage disequilibrium
between polymorphisms might provide a means to understand
5FU-related toxicity in patients. Hitherto, several clinical trials
were analyzed on the basis of the concept that genotyping the
TYMS VNTR alone would give an estimate of Tyms protein levels
in normal tissues and tumors and therefore help in dosing patients
with 5FU. Clinical reports have also related the TYMS VNTR to
5FU-related toxicity. The design of these studies, however, omitted
a comprehensive examination of the genetic variation in the TYMS
genetic region.
Minisatellites, or VNTRs, can arise readily due to mispairing of
repeats in an array [32], particularly by slipped-strand mispairing
during DNA replication, by unequal sister chromatin exchange
(USCE) during mitosis or meiosis, or by unequal crossover
between homologous chromosomes (interallelic recombination)
during meiosis. VNTRs can also mutate by gaining or losing
repeats one at a time [33]. There is a high mutation rate at VNTR
loci, causing the same mutation to occur independently (in
parallel) in different lineages (termed homoplasy or homoplasious
alleles), which can be mistaken for homologous alleles (inheritance
due to common ancestry) [26,27,28]. The TYMS VNTR variants
do not conform to the patterns expected from common ancestry
and are therefore concluded to be homoplasious, evolving rapidly,
in contrast to the SNPs in the same region. Due to homoplasy, the
SNP haplotypes and VNTR types both would need to be
determined to define precise TYMS genotypes.
Our genotyping data therefore reveal a weak association
between SNP haplotypes and the VNTR types. We observe the
different VNTR types occurring on any given SNP haplotype
(Figure 3), indicating that the VNTR evolved at a faster rate than
the SNP haplotype. The most common VNTR, 2R, occurred in a
common haplotype of our hospital-based population. Previous
clinical literature reported the 2R/2R genotype to be associated
Table 2. Polymorphism among mononucleotide repeats near the TYMS promoter.
Mononucleotide repeat No. of samples examined Position in genome
1 Polymorphism observed
MR1 (A15GA9) 32 655,156–655,180 None
MR2 (A24) 32 655,323–655,346 2–5 bp variation
MR3 (T14C4) 32 656, 030–656,047 2–3 bp variation
MR4 (A11) 32 656,712–656,722 None
MR5 (A16) 20 656,871–656,886 None
MR6 (T26) 22 656,933–656,958 2–3 bp variation
1UCSC genomic build GRCh37/hg19.
doi:10.1371/journal.pone.0034426.t002
Table 3. Length variability (polymorphism) within the MR2
repeat.
Sample Peak location Peak height
1 Peak width
2
PN8 245 1435 2
PN9 250 1572 3
PN33 249 3963 2
PN38 245 1176 3
PN79 245 1206 3
PN104 245 2904 2
PN9+PN104 (1:2) 247 1754 4–5
3
1Machine-generated measurement of DNA length at the top of the observed
peak, in nucleotide scale.
2Peak width at half-maximal heights of both peak slopes, in nucleotide scale.
3The peak width was between 4 and 5 nucleotides (half-maximal peak height
for this sample was more than 4 nucleotides but less than 5). Analysis of the
graphs from mixtures made of differing ratios produced a migration of the peak
as expected, confirming a variation in the polymorphic forms of samples PN9
and PN104.
doi:10.1371/journal.pone.0034426.t003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34426Figure 2. The nine most common SNP haplotypes. Common haplotypes and estimated haplotype frequencies as determined using Haploview
across the region under survey. Numbers on top of the figure indicate the ‘SNP number’ from the 80 kb analyzed region (refer Figure 1A) as listed in
Table S2. Numbers in the middle reflect frequencies of the individual haplotype. These frequencies sum up to the numbers at the bottom because
they reflect only fairly common haplotypes (i.e., the number at the end ‘0.94’, explains frequencies of 94% of individuals, the rest of the individuals
have rare haplotypes).
doi:10.1371/journal.pone.0034426.g002
Figure 3. Estimated haplotype frequencies for common haplotype blocks ($1%) containing a given VNTR type. Haplotypes that
included the VNTR were estimated in 322 Caucasian patients using the following marker alleles: rs1001761, VNTR, rs699517, rs3744962, rs9948583,
rs495139, rs2298582, rs2298581, rs2471186, rs7236747, and rs2612092. VNTR data was available for 31 patients. Each color represents one SNP-
defined haplotype, for SNPs located in blocks 7 and 8 of Figure 1B. The observed frequency (in 31 individuals, 62 chromosomes) for each VNTR is as
follows: 2R (50%), 3Rc (32%), and 3Rg (18%). The estimated haplotype frequency of association of the indicated VNTR/haplotype pair is shown and
the standard error (SE) is indicated.
doi:10.1371/journal.pone.0034426.g003
TYMS Polymorphisms
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those studies [17,18,19] suggested that the 2R repeat itself might
not cause differences in Tyms expression, but might be linked
genetically to the causative genetic variation in some populations.
If the 2R/2R genotype arose due to homoplasy and not due to
common ancestry, an apparently homozygous patient in actuality
need not have two copies of the same ancestral allele. Therefore,
knowledge of both VNTR and surrounding genetic polymor-
phisms of an individual may be required to define a genetic
haplotype that can be associated with a phenotype. For example, a
clinical trial could be designed to examine the association between
the extended genetic haplotypes in this region and the undesired
occurrence of 5FU toxicity.
Mononucleotide repeats occur throughout the human genome.
They often harbor mutations [34] and polymorphism [35],
providing useful markers for genetic mapping. The presence of
six arrays of poly(A) or poly(T) in the TYMS promoter region
makes the genetic structure of TYMS 59-UTR interesting, aside
from their potential as markers. The polymorphic repeats might
conceivably affect TYMS promoter function directly. Also, upon
5FU administration, fluorouridine misincorporation in DNA
might be concentrated in these tracts, perhaps amplifying
deoxythymidylate depletion if local repair might interfere with
promoter function [36,37]. This is speculative, but suggests a
number of questions to be addressed in future work.
A direct effect of the VNTR on drug response is not supported
by our findings. Our studies indicate that the VNTR is
homoplasious and therefore should not be uniformly associated
with a putative linked locus associated with risk of toxicity.
Genotyping in the TYMS region should consider the surrounding
polymorphisms, because it is possible that a robust predictive
marker could emerge from one of the stable changes (like SNPs)
assayed here, because the VNTR was inconsistently linked
empirically to 5FU toxicity, and because the VNTR is not likely
causative of the toxicity [17,18,19]. In the literature, when
‘moving’ from one genetically related population (where the
association or linkage may be high) to another population (where
the linkage may be weak), the VNTR would lose its linkage as a
marker for toxicity. In our study therefore, we looked into other
polymorphisms in the TYMS 59UTR region with the idea of
finding stable mutations not subject to homoplasy, which could
serve as markers having greater stability for comparing less-related
populations.
A broader perspective also remains essential. Showalter et al
[38] analyzed prior studies related to Tyms expression levels and
response to 5FU chemotherapy. Little difference was found among
response rates between tumors having low- and high-Tyms
expression upon analyzing the grouped data. Although admittedly
some articles had used greater sophistication in Tyms protein
determinations, the authors expressed doubt that a compelling
clinical utility had been found in these reports. A recently
conducted pilot study concluded that TYMS expression and
genotyping based on the 59UTR repeats have no significant
impact on the clinical outcome of cancer patients treated with 5FU
[39]. Several other variables may affect Tyms expression and 5FU
therapy, other than the proposed TYMS genetic polymorphisms.
Patients with deficiency in dihydropyrimidine dehydrogenase, the
rate-limiting enzyme of pyrimidine catabolism in the 5FU
metabolic pathway to the inactive 5-fluoro-5, 6-dihydrouracil,
suffer from severe 5FU toxicity [40]. Variable 5FU toxicity might
relate to variation in methylene tetrahydrofolate reductase, which
forms the reduced folate cofactor essential for inhibiting Tyms
[20]. Orotate phosphoribosyl-transferase (Oprt), the enzyme
necessary for stabilization and formation of the ternary complex
[41] following 5FU treatment is also a potential predictor of 5FU
effects [42]. The G213A polymorphism in OPRT is reported to be
associated with grade 3–4 toxicity in response to 5FU therapy
[19]. In addition to Tyms levels or the TYMS genotypes, there
could be a combination of enzymes in the 5FU metabolic pathway
or even deficiencies in dietary folate that could affect 5FU
response. Investigators studying TYMS-5FU interactions will need
to consider these and other possibilities.
Based on our results, we suggest that the understanding of
TYMS repeats to guide 5FU therapy should be updated. In hopes
of determining an empirical basis for predicting 5FU toxicity,
VNTR and mononucleotide repeats should be genotyped along
with a determination of SNPs in the region to define a complete
haplotype.
Materials and Methods
Patient samples and IRB approval
Constitutional DNA was extracted from normal frozen tissue of
363 pancreatic cancer patients (proteinase K/phenol: chloroform
or by Qiagen DNA tissue kit). Tissues for genetic research were
used upon written consent under a protocol approved by our IRB,
the Joint Committee on Clinical Investigation of The Johns
Hopkins University School of Medicine and The Johns Hopkins
Hospital. Demographic information including age, gender and
ethnicity was obtained from the medical records.
Primer design, PCR, and sequence analysis
Primers were synthesized by Integrated DNA Technologies
(Sequences are available upon request). Primers for analysis of
mononucleotide repeats had a 59FAM modification in the forward
primer for analysis by CE. After PCR using Taq DNA
polymerase, products were separated on 1% agarose gel in lithium
boric acid buffer (LBH, FasterBetter Media LLC) [43], purified
(QIAquick PCR Purification Kit, Qiagen), and analyzed by
automated sequencing and by the Sequencher program (Gene
Codes).
Lengths of mononucleotide repeats
Primer pairs flanking each mononucleotide repeat were used to
PCR-amplify six fragments of interest (Figure S1). Following PCR,
we polished the ends of the amplified products using Klenow (NEB
# M0210, per manufacturer’s instruction) to eliminate size
variation due to varying addition of non-templated adenosines.
The polished products were first analyzed on a 1% agarose gel,
and then mixed with a size standard and formamide, heat-
denatured, and fragments resolved using CE.
SNPs from public database for haplotype analysis
We selected SNPs (listed in Table S2) from the HapMap
database http://hapmap.ncbi.nlm.nih.gov/biomart/martview,
(mainly from Caucasians), and a few common SNPs from the
African-American population. The SNPs spanned an 80 kb region
(Figure 1A) that included 57 kb upstream of the TYMS start
codon, the entire TYMS gene (inclusive of exons and introns, 16.
5 kb), and about 6.5 kb downstream of the TYMS stop codon. We
reasoned that the 80 kb region would possibly encompass the
regulatory elements and polymorphisms responsible for Tyms
expression. Novel SNPs identified in our sequence analysis were
incorporated into our genotyping panel as described.
SNP genotyping
A total of 147 SNPs were genotyped (Illumina BeadXpress
array). Eleven SNPs were excluded, eight due to call rates of zero
TYMS Polymorphisms
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(Table S2), the minimum call rate was 99.1%. Of the 363 patient
DNA samples, seven were not included in the assay due to low
DNA quantity, and five samples failed genotyping. The minimum
call rate in the remaining individuals was 99.2%. Overall,
genotype data was available for 182 males and 169 females. Of
the 351 genotyped, 322 reported Caucasian ancestry, and the
remaining 29 belonged to other ethnic groups. Data cleaning was
conducted using PLINK [44].
Haplotype analysis
Haplotype analysis was conducted using Haploview [45] for the
Caucasian population. Eighteen SNPs were monomorphic in the
Caucasian subset, and eight had a MAF (minor allele frequency)
,1%; these SNPs were excluded from haplotype analysis. All
remaining SNPs had a HWE (Hardy-Weinberg Equilibrium) p-
value .0.001. Blocks were defined using the Gabriel et al method
[25]. In the Caucasian population, additional haplotype analysis
including the VNTR repeats was conducted using PHASE 2.1.1
[46]. To estimate the haplotype frequency in Caucasians for the
haplotype containing the VNTR, haplotype-tagging SNPs were
selected using the TAGGER program with the aggressive mode
(2.3 marker haplotype) and an r
2 threshold of 0.95 [45]. Using the
haplotype-tagging SNPs in the haplotype block containing the
VNTR or the 39 UTR, along with the VNTR or 39 UTR
polymorphisms, haplotype frequencies were estimated using
PHASE.
Supporting Information
Figure S1 Structure of the TYMS genetic region. The
structure of the TYMS genetic region from coordinates 654,843–
657,842 (UCSC genomic build GRCh37/hg19) is shown. The
mononucleotide repeats (MR) and VNTR appear as bold
underlined letters. The coordinates of the MR are reported in
Table 2. The TYMS promoter is in italics. The primers used to
amplify the MR are listed.
(DOC)
Figure S2 Enlarged version of figure 1B (in main
document). Nine haplotype blocks (in triangular shape) were
obtained by haplotype analysis using Haploview (see Materials and
Methods), covering the 80 kb TYMS genetic region (depicted in
Figure 1A). The reference SNP numbers (rs) are shown on top.
The linkage disequilibrium (D9) is indicated in the small boxes
colored red or blue as indicated by the color legend. The boxes in
red or pink depict D9 to have very good correlation between SNPs.
The boxes in blue or white indicate D9 to have poor correlation.
Some newly discovered SNPs that were not in the public database
at the time of analysis were named as TYMS_SG 1, 2, 3, 16,19, 22,
and 24. At the time of submission of the new SNPs, we noticed they
were deposited by others and had an assigned SNP numbers of
rs12964837, rs11872762, rs11877806, rs36124867, rs75363899,
rs2853533, and rs72634355 respectively.
(TIF)
Figure S3 Enlarged version of figure 1C (in main
document). The largest haplotype block spanning the TYMS
gene and some parts in the 59 UTR, including the VNTR and the
mononucleotide repeats, and the 39UTR, is expanded. Blocks 1
and 2 in this figure correspond to blocks 8 and 9 respectively, of
Figure 1B (in main document). The unmatched marker 87
corresponding to SNP number rs3826626 was removed in this
figure. The locations of the VNTR, the MR (mononucleotide
repeats), and the 6-bp deletion/insertion polymorphism are given.
The TYMS translational start codon is 13 bp downstream of the
VNTR.
(TIF)
Table S1 New SNPs identified in this study from the
TYMS genetic region.
(DOC)
Table S2 A complete list of SNPs used for genotyping in
this study.
(DOC)
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